ArticleThe oncologist2022

FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.

Najat Bouchkouj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.